The BRAFmut/MSS cancers showed no difference in rate of CIMP in the proximal (17/27, 63.0%) versus distal bowel (6/12, 50%), rate of p53 mutation in the proximal (14/31, 45.2%) or distal bowel (6/14, 42.9%), or in stage at diagnosis in the proximal (10/21, 47.6%) versus distal bowel (4/9, 44.4%). Here, TP53 is linked to cancer.